Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic LeukemiaElias Jabbour, Josep‐María Ribera, Maria R. Baer et al.|JAMA|2024Cited by 119
Tourmaline US-MM6, an Open-Label, Single-Arm, Multicenter Study Evaluating the Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Switching from a Bortezomib-Based Triplet Induction RegimenRobert M. Rifkin, Stephen J. Noga, Ralph V. Boccia et al.|Blood|2017Cited by 5
Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (btz) to Ixazomib: The US MM-6 Community-Based StudyStephen J. Noga, Ralph V. Boccia, Robert M. Rifkin et al.|Blood|2019Cited by 4